Theracos

Recent Finacing

Hybrid

Recent Raise

$25M

TheracosBio develops and commercializes bexagliflozin (an SGLT2 inhibitor) for adult Type 2 diabetes in the U.S., operates ongoing Phase IIb dosing trials and coordinates veterinary commercialization with Elanco.

Founded 2000

Massachusetts, United States

1-10

Private

theracos.com

Highlights

Focus Areas

Biotechnology

Health Care

Pharmaceutical

Financials

$25M

Total Raised

1

Funding round

1

Investor

Team

Upgrade to view the team

See the team members at Theracos.